Company Profile · Healthcare

Aurisco Pharmaceutical Co Ltd

605116 · Shanghai
Country
China
Employees
2,026
Buffett Score
62/100
Medium
Market capCN¥8.15B
Revenue (TTM)CN¥1.7B
EBITDACN¥639.07M
Profit margin21.89%
ROE14.62%
P/E (TTM)22.05
Forward P/E0
EPSCN¥0.91
Dividend yield1.76%
52-week rangeCN¥17.79 – CN¥34.98

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for the treatment of asthma, respiratory tract diseases, and rhinitis; Tenofovir, an anti-infection used to treat AIDS and hepatitis B; pregabalin for the treatment of anti-epileptic, analgesic, and anti-anxiety purposes, as well as for neuralgia; abiraterone acetate to treat prostate cancer; and dydrogesterone, to treat endogenous for women's heath. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

No reports on this stock in your language yet.